Clay Siegall Leads Seattle Genetics in finding Cancer Therapies

Dr. Clay Siegall, the CEO, and founder of Seattle Genetics is an influential role player in a team of researchers trying to find cancer treatment. In a recent interview on the plans by Seattle Genetics to develop cancer drugs, Siegall expressed hope about Seattle Genetics announcing the discovery of more cancerous tumors medicine soon.

21st Century Drug for Cancer

Under the leadership of the legendary Dr. Clay Siegall, Seattle Genetics seems well-positioned to revolutionize the targeted methods to treat cancer in the 21st Century. Seattle Genetics is a Seattle-based biotech company specializing in the research and development of therapy medicines to cure the diseases contributing to high mortality rates.

“The traditional cancer treatment strategies, such as chemotherapies, belong to the dustbin,” says Siegall. “Only targeted therapies and drugs will cure tumors, effectively.”

Dr. Siegall, who graduated from The University of Maryland with a B.S. in zoology and also holds a Ph.D. in genetics from the George Washington University founded Seattle Genetic in 1998. Siegall’s firm was the first to develop an antibody drug conjugate approved by the FDA. In collaboration with reputable drug manufacturers, such as Pfizer, Bayer, and Genentech, Seattle Genetics has over 20 drugs in the pipeline.

Deep Interest in Medicine

The inspiration to start Seattle Genetics in 1998, explains Dr. Clay Siegall, arose because of his interest in technology, medicine, and the desire to cure people who without any intervention would just die. One of Siegall’s family member struggled with cancer as Dr. Clay Siegall studied zoology. The family member endured brutal treatment regimens, which led to the development of severe anemia.

After seeing the harmful effects of chemotherapy, Clay started to think of better ways to cure cancer. Under the guidance of Dr. Clay Siegall, Seattle Genetics has several antibody-based cancer drugs to its name, for instance, ADCETRIS (brentuximab vedotin), which the U.S. Food and Drug Administration approved in 2011.

Clay worked for the Bristol-Myers Squibb Pharmaceutical Research Institute, National Cancer Institute, and National Institutes of Health between 1988 and1997. Dr. Siegall has 15 patents to his name and has authored over 70 publications.